| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CLMF; CLMF p40; CLMF2; IL12 p40; IL12B; IMD28; IMD29; NKSF; NKSF2;;IL 12B |
| WB Predicted band size | Calculated MW: 37 kDa ; Observed MW: 75,40 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human IL 12B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于IL12B抗体的3-4篇参考文献示例(内容为模拟概括，建议通过学术数据库核实原文)：
1. **"Targeting IL-12/IL-23p40 in Psoriasis: A Phase III Study of Ustekinumab"**
- **作者**: Griffiths CEM, et al.
- **摘要**: 该研究评估了抗IL12B(靶向IL-12/IL-23共同亚基p40)的单抗药物Ustekinumab在中重度银屑病患者中的疗效和安全性。结果显示，与安慰剂相比，治疗组患者皮损显著改善，且耐受性良好。
2. **"Structural Basis of IL-12B Recognition by a Therapeutic Antibody"**
- **作者**: Zhang Y, et al.
- **摘要**: 通过X射线晶体学解析了抗IL12B单抗与IL-12p40亚基的结合机制，揭示了抗体通过阻断IL-12与受体结合发挥治疗作用的分子基础，为优化抗体药物设计提供了依据。
3. **"IL-12B Deficiency Increases Susceptibility to Mycobacterial Infection in Humans"**
- **作者**: Cooper AM, et al.
- **摘要**: 研究报道了IL12B基因缺陷患者对分枝杆菌感染的易感性增加，表明IL-12B在抗细胞内病原体的免疫应答中起关键作用，为开发靶向IL12B的免疫调节疗法提供了理论支持。
4. **"Anti-IL12B Antibody Attenuates Experimental Colitis by Modulating Th1 Responses"**
- **作者**: Hueber W, et al.
- **摘要**: 在小鼠结肠炎模型中，抗IL12B抗体通过抑制Th1细胞分化和促炎细胞因子分泌，显著减轻肠道炎症，提示其在炎症性肠病(如克罗恩病)中的潜在治疗价值。
**注意**：以上文献名为示例，实际引用时需根据具体研究内容检索PubMed、Google Scholar等数据库获取准确信息。
**Background of IL12B Antibodies**
IL12B antibodies target the interleukin-12 subunit beta (IL12B), a key component of the pro-inflammatory cytokine IL-12. IL-12. composed of IL12B (p40) and IL-23A (p19) subunits, plays a critical role in bridging innate and adaptive immunity by promoting Th1 cell differentiation, IFN-γ production, and cytotoxic T/NK cell activation. Dysregulated IL-12 signaling is implicated in autoimmune diseases (e.g., psoriasis, inflammatory bowel disease) and chronic inflammation.
IL12B-specific antibodies are designed to neutralize IL-12 activity by blocking its p40 subunit, which is shared with IL-23. This dual inhibition underpins the therapeutic efficacy of drugs like ustekinumab, an FDA-approved IL12B antibody used to treat psoriasis, psoriatic arthritis, and Crohn’s disease. By disrupting the IL-12/IL-23 axis, these antibodies reduce pathological inflammation driven by excessive Th1/Th17 responses.
Research also explores IL12B antibodies in infectious contexts, as IL-12 is vital for combating intracellular pathogens. However, therapeutic targeting requires balancing immune suppression and infection risk. Ongoing studies aim to refine specificity and applications, including cancer immunotherapy, where IL-12’s role in anti-tumor immunity is being investigated. Overall, IL12B antibodies represent a pivotal tool in modulating immune pathways for clinical benefit.
×
